MNKD is back at a frequent level of "traffic" this week. After doing a quick retracement we can see that the 618 area continues to act as a magnate a key pivot area. After bouncing off this last time, MNKD has continued higher on a decent multi-day move. Now, moving forward, a fundamental focus could be on what happens with its next potential commercial product,...
Rapidly Hiring. They have a proprietary drug delivery platform known as the Technosphere. They deliver drugs through the lungs instead of injection or pills.
Afrezza their FDA approved drug is finally starting to generate sales after being fda approved years ago.
They are also working on several other products for 2020.
Huge accumulation range and due to...
Trend continuation, possible bullish outlook as long as price can stay above channel.
MNKD (with partner Sanofi) is about to market and distribute FDA approved Afrezza, a inhaled insulin that can make insulin syringes a thing of the past. With diabetes a global condition that effects 371 million people worldwide and is expected to affect 552 million by 2030,...
